Akeso has shared for the first time overall survival data from a high-profile Keytruda head-to-head trial for its PD-1xVEGF bispecific ivonescimab—and investors in the company's partner Summit ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results